Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. more
Time Frame | CMMB | Sector | S&P500 |
---|---|---|---|
1-Week Return | 6.33% | -2.12% | -3% |
1-Month Return | 2.44% | -3.42% | -0.73% |
3-Month Return | -1.75% | -11.13% | 2.87% |
6-Month Return | 80.65% | -5.74% | 7.17% |
1-Year Return | 230.06% | 3.97% | 25.31% |
3-Year Return | -73.79% | 1.05% | 28.38% |
5-Year Return | -92.61% | 34.37% | 81.89% |
10-Year Return | -99.03% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 281.00K | 80.00K | 34.02K | 57.77K | 66.83K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":28.47,"profit":true},{"date":"2021-12-31","value":12.11,"profit":true},{"date":"2022-12-31","value":20.56,"profit":true},{"date":"2023-12-31","value":23.78,"profit":true}] |
Gross Profit | (281.00K) | (80.00K) | (34.02K) | (57.77K) | (66.83K) | [{"date":"2019-12-31","value":-28100000,"profit":false},{"date":"2020-12-31","value":-7999900,"profit":false},{"date":"2021-12-31","value":-3402300,"profit":false},{"date":"2022-12-31","value":-5777300,"profit":false},{"date":"2023-12-31","value":-6682700,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 22.90M | 5.97M | 12.37M | 28.53M | 25.46M | [{"date":"2019-12-31","value":80.25,"profit":true},{"date":"2020-12-31","value":20.93,"profit":true},{"date":"2021-12-31","value":43.34,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.23,"profit":true}] |
Operating Income | 27.12M | (5.97M) | (12.40M) | (28.53M) | (25.46M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-22.02,"profit":false},{"date":"2021-12-31","value":-45.72,"profit":false},{"date":"2022-12-31","value":-105.19,"profit":false},{"date":"2023-12-31","value":-93.86,"profit":false}] |
Total Non-Operating Income/Expense | (7.58M) | 35.00K | (222.00K) | 706.00K | 2.48M | [{"date":"2019-12-31","value":-305.98,"profit":false},{"date":"2020-12-31","value":1.41,"profit":true},{"date":"2021-12-31","value":-8.97,"profit":false},{"date":"2022-12-31","value":28.51,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | 27.12M | (5.95M) | (12.48M) | (28.18M) | (24.22M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-21.94,"profit":false},{"date":"2021-12-31","value":-46,"profit":false},{"date":"2022-12-31","value":-103.89,"profit":false},{"date":"2023-12-31","value":-89.3,"profit":false}] |
Income Taxes | - | (21.00K) | 77.00K | (534.00K) | (1.00) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-27.27,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-693.51,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | (5.93M) | (12.55M) | (27.65M) | (24.22M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-593000000,"profit":false},{"date":"2021-12-31","value":-1255500000,"profit":false},{"date":"2022-12-31","value":-2764600000,"profit":false},{"date":"2023-12-31","value":-2422099900,"profit":false}] |
Income From Continuous Operations | (27.12M) | (11.61M) | (12.48M) | (27.65M) | (24.22M) | [{"date":"2019-12-31","value":-2712400000,"profit":false},{"date":"2020-12-31","value":-1160900000,"profit":false},{"date":"2021-12-31","value":-1247800000,"profit":false},{"date":"2022-12-31","value":-2764600000,"profit":false},{"date":"2023-12-31","value":-2422100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 27.12M | (5.93M) | (12.55M) | (27.65M) | (24.22M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-21.86,"profit":false},{"date":"2021-12-31","value":-46.29,"profit":false},{"date":"2022-12-31","value":-101.92,"profit":false},{"date":"2023-12-31","value":-89.3,"profit":false}] |
EPS (Diluted) | (63.20) | (8.24) | (1.18) | (1.06) | (1.12) | [{"date":"2019-12-31","value":-6320,"profit":false},{"date":"2020-12-31","value":-824,"profit":false},{"date":"2021-12-31","value":-118,"profit":false},{"date":"2022-12-31","value":-106,"profit":false},{"date":"2023-12-31","value":-112.14,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CMMB | |
---|---|
Cash Ratio | 4.46 |
Current Ratio | 4.57 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CMMB | |
---|---|
ROA (LTM) | -46.18% |
ROE (LTM) | -93.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CMMB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CMMB | |
---|---|
Trailing PE | NM |
Forward PE | 13.00 |
P/S (TTM) | 0.00 |
P/B | 1.94 |
EV/R | 0.00 |
EV/Ebitda | 0.33 |
Chemomab Therapeutics Ltd DRC (CMMB) share price today is $1.68
Yes, Indians can buy shares of Chemomab Therapeutics Ltd DRC (CMMB) on Vested. To buy Chemomab Therapeutics Ltd DRC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CMMB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Chemomab Therapeutics Ltd DRC (CMMB) via the Vested app. You can start investing in Chemomab Therapeutics Ltd DRC (CMMB) with a minimum investment of $1.
You can invest in shares of Chemomab Therapeutics Ltd DRC (CMMB) via Vested in three simple steps:
The 52-week high price of Chemomab Therapeutics Ltd DRC (CMMB) is $2.55. The 52-week low price of Chemomab Therapeutics Ltd DRC (CMMB) is $0.45.
The price-to-earnings (P/E) ratio of Chemomab Therapeutics Ltd DRC (CMMB) is
The price-to-book (P/B) ratio of Chemomab Therapeutics Ltd DRC (CMMB) is 1.94
The dividend yield of Chemomab Therapeutics Ltd DRC (CMMB) is 0.00%
The market capitalization of Chemomab Therapeutics Ltd DRC (CMMB) is $30.55M
The stock symbol (or ticker) of Chemomab Therapeutics Ltd DRC is CMMB